Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024:2806:139-151.
doi: 10.1007/978-1-0716-3858-3_11.

Generation of Metastatic Cholangiocarcinoma Patient-Derived Xenograft Models

Mariana Yáñez-Bartolomé #  1 , Queralt Serra-Camprubí #  1 , Enrique J Arenas  2 , Marta Escorihuela  3 , Florian Castet  1 , Carles Fabregat-Franco  1 , Jessica Querol  1 , Joaquín Arribas  3   4   5   6   7 , Sandra Peiró  1 , Teresa Macarulla  8 , Tian V Tian  9
Affiliations

Generation of Metastatic Cholangiocarcinoma Patient-Derived Xenograft Models

Mariana Yáñez-Bartolomé et al. Methods Mol Biol. 2024.

Abstract

Cholangiocarcinoma (CCA) poses a substantial clinical hurdle as it is often detected at advanced metastatic stages with limited therapeutic options. To enhance our understanding of advanced CCA, it is imperative to establish preclinical models that faithfully recapitulate the disease's characteristics. Patient-derived xenograft (PDX) models have emerged as a valuable approach in cancer research, offering an avenue to reproduce and study the genomic, histologic, and molecular features of the original human tumors. By faithfully preserving the heterogeneity, microenvironmental interactions, and drug responses observed in human tumors, PDX models serve as highly relevant and predictive preclinical tools. Here, we present a comprehensive protocol that outlines the step-by-step process of generating and maintaining PDX models using biopsy samples from patients with advanced metastatic CCA. The protocol encompasses crucial aspects such as tissue processing, xenograft transplantation, and subsequent monitoring of the PDX models. By employing this protocol, we aim to establish a robust collection of PDX models that accurately reflect the genomic landscape, histologic diversity, and therapeutic responses observed in advanced CCA, thereby enabling improved translational research, drug development, and personalized treatment strategies for patients facing this challenging disease.

Keywords: Advanced Cholangiocarcinoma (CCA); Biopsy; Patient-derived xenografts (PDXs).

PubMed Disclaimer

References

    1. Banales JM, Cardinale V, Carpino G et al (2016) Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 13(5):261–280. https://doi.org/10.1038/nrgastro.2016.51 - DOI - PubMed
    1. Banales JM, Cardinale V, Macias RIR et al (2019) Cholangiocarcinoma: state-of-the-art knowledge and challenges. Liver Int 39(Suppl 1):5–6. https://doi.org/10.1111/liv.14101 - DOI - PubMed
    1. Ilyas SI, Affo S, Goyal L et al (2023) Cholangiocarcinoma – novel biological insights and therapeutic strategies. Nat Rev Clin Oncol 20(7):470–486. https://doi.org/10.1038/s41571-023-00770-1 - DOI - PubMed - PMC
    1. Banales JM, Marin JJG, Lamarca A et al (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17(9):557–588. https://doi.org/10.1038/s41575-020-0310-z - DOI - PubMed - PMC
    1. Calvisi DF, Boulter L, Vaquero J et al (2023) Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance. Nat Rev Gastroenterol Hepatol 20(7):462–480. https://doi.org/10.1038/s41575-022-00739-y - DOI - PubMed

Publication types

LinkOut - more resources